FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
vvasilington,	D.C.	20040

STATEMENT	OF CHANGES	IN BENEFICIAL	OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Mubadala Investment Co PJSC		2. Issuer Name and Ticker or Trading Symbol RECURSION PHARMACEUTICALS, INC. [RXRX]							Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner Officer (give title Other (specify)									
						Date of Earliest Transaction (Month/Day/Year) /01/2023							below) below)					
(Street) ABU DHABI CO 00000				4. If <i>i</i>	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person X Porress Reporting						
(City) (State) (Zip)														Perso	on			
			I - Non-Deriv			ies Ad	quir	_	_						ed		1	
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)		Transaction Code (Instr.		4. Securities Acquired (Disposed Of (D) (Instr. 3				5. Amount of Securities Beneficially Owned Following			6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficia	of Indirect Il ip (Instr. 4)		
							v	Amoun	nt (A) or (D)		Price		Reported Transaction(s) (Instr. 3 and 4)					
Class A (Common St	ock	03/01/2023			P		48,86	57	A	\$7.9	416(1)	1	12,919,105	5	I See Explanati of Responses (4)(5)		
Class A (Common St	ock												7,062,869	62,869 See Explanation of Responses ⁽³⁾ (4)(5)			
		Та	ble II - Derivat (e.g., p												d			
Derivative Conversion Dat		3. Transaction Date (Month/Day/Year)	e Execution Date, nth/Day/Year) if any		Transaction of Code (Instr. 8) Se Ac (A) Dis of (In the control of Code (Instr. 8)		of Exp		Date Exercisable and Diration Date on the Date on the Date on the Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Inst 3 and 4)		Derivative Security (Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	or Nun Date Expiration of		Numb	oer														
		f Reporting Person tment Co PJS																
(Last)	X 45005	(First)	(Middle)		-													
(Street)	HABI	C0	00000		_													
(City)		(State)	(Zip)															
		Reporting Person sified Global	Holding PJS	<u>C</u>														
(Last) P. O. BO	X 45005	(First)	(Middle)															
(Street)	HABI	C0	UAE		_													

Explanation of Responses:

(State)

(Zip)

(City)

^{1.} The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from \$7.84 to \$7.97, inclusive. The reporting person undertakes to provide to Recursion Pharmaceuticals, Inc. (the "Issuer"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Form 4.

^{2.} Consists of 12,919,105 shares held of record by Fifteenth Investment Company LLC. Fifteenth Investment Company LLC is a wholly owned subsidiary of Mamoura Diversified Global Holdings PJSC, which is wholly owned by Mubadala Investment Company PJSC, which is wholly owned by the Government of Abu Dhabi.

- 3. MDC Capital Partners (Ventures) GP, LP is the general partner of MDC Capital Partners (Ventures), LP, which directly holds 7,062,869 shares of Class A Common Stock ("Class A Shares"). MDC Capital Partners (Ventures) GP, LP has created an investment committee comprised of four individual members, which has the authority, by affirmative majority consent, to approve all investment and divestment decisions made with respect to MDC Capital Partners (Ventures), LP. Each of the members of the investment committee expressly disclaims beneficial ownership of the shares held by MDC Capital Partners (Ventures), LP.
- 4. Because of the relationship among the Reporting Persons, the Reporting Persons may be deemed to own the securities reported herein to the extent of their respective pecuniary interests. Each Reporting Person disclaims beneficial ownership of the securities reported herein, except to the extent of such Reporting Person's pecuniary interest therein, if any.
- 5. Pursuant to Rule 16a-1(a)(4) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), this filing shall not be deemed an admission that the Reporting Persons are, for purposes of Section 16 of the Exchange Act or otherwise, the beneficial owners of any equity securities in excess of their respective pecuniary interests.

Remarks:

6. The Reporting Persons are jointly filing this Form 4 pursuant to Rule 16a-3(j) under the Exchange Act.

/s/ Samer Halawa, Chief Legal
Officer, Mubadala Investment
Company PJSC (6)
/s/ Samer Halawa, Chief Legal
Officer, Mamoura Diversified
Global Holdings PJSC (6)

Date

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.